prostate-specific membrane antigen peptide-pulsed autologous peripheral blood mononuclear cells

Prostate-specific membrane antigen peptide-pulsed autologous peripheral blood mononuclear cells is an investigational autologous cellular immunotherapy designed to treat prostate cancer. The therapeutic process involves harvesting a patient's own peripheral blood mononuclear cells (PBMCs) via leukapheresis, which are then pulsed ex vivo with specific synthetic peptides derived from the prostate-specific membrane antigen (PSMA). PSMA is a type II transmembrane glycoprotein that is significantly overexpressed in nearly all prostate cancer cells, with expression levels often increasing in higher-grade and metastatic disease. Once re-infused into the patient, the antigen-presenting cells (APCs), primarily dendritic cells within the PBMC population, present these PSMA epitopes to the host immune system. This interaction aims to prime and expand a population of PSMA-specific cytotoxic T lymphocytes (CTLs) that can selectively recognize and lyse malignant cells expressing PSMA. This personalized vaccine approach has been primarily investigated in Phase 1 and Phase 2 clinical trials for patients with metastatic castration-resistant prostate cancer (mCRPC).

Other names

PSMA-pulsed autologous PBMCsPSMA peptide-pulsed autologous PBMCsPSMA-pulsed dendritic cell vaccineautologous PSMA-pulsed PBMCs